60 Degrees Pharma Sets Jan 2027 Data Readout, Plans FDA Pre-sNDA Meeting

60 Degrees Pharmaceuticals plans to unblind results from its 30-patient severe babesiosis trial in January 2027. The company also intends to seek a pre-sNDA meeting with the FDA in the same month to discuss a potential accelerated approval pathway based on NAT clearance.